Combined chemotherapy and intensity-modulated radiotherapy for the treatment of head and neck cancers

References

• Kelly C, Paleri V, Downs C et al. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol. Head Neck Surg.136, 108–111 (2007).
   PubMed Web of Science ®Google Scholar
• Nutting C, A’Hern R, Rogers MS et al. First results of a Phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J. Clin. Oncol.27, 18s (2009).
   Google Scholar
• Trotti A, Bellm LA, Epstein JB et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother. Oncol.66, 253–262 (2003).
   PubMed Web of Science ®Google Scholar
• Mendenhall WM. Mandibular osteoradionecrosis. J. Clin. Oncol.22, 4867–4868 (2004).
   PubMedGoogle Scholar
• Bhide SA, Harrington KJ, Nutting CM. Otological toxicity after postoperative radiotherapy for parotid tumours. Clin. Oncol. (R. Coll. Radiol.)19, 77–82 (2007).
   PubMed Web of Science ®Google Scholar
• Hammerlid E, Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. Br. J. Cancer84, 149–156 (2001).
   PubMed Web of Science ®Google Scholar
• Chao KS, Deasy JO, Markman J et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int. J. Radiat. Oncol. Biol. Phys.49, 907–916 (2001).
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Marsh LH, Martel MK et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. Int. J. Radiat. Oncol. Biol. Phys.41, 559–568 (1998).
   PubMedGoogle Scholar
• Feng FY, Kim HM, Lyden TH et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int. J. Radiat. Oncol. Biol. Phys.68, 1289–1298 (2007).
   PubMed Web of Science ®Google Scholar
• Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J. Clin. Oncol.25, 4873–4879 (2007).
   PubMed Web of Science ®Google Scholar
• Pow EH, Kwong DL, McMillan AS et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int. J. Radiat. Oncol. Biol. Phys.66, 981–991 (2006).
   PubMed Web of Science ®Google Scholar
• Guerrero Urbano T, Clark CH, Hansen VN et al. A Phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother. Oncol.85, 36–41 (2007).
   PubMedGoogle Scholar
• Bhide S, Guerrero Urbano MT, Clark C et al. Results of intensity modulated radiotherapy (IMRT) in laryngeal and hypopharyngeal cancer: a dose escalation study. Radiother. Oncol.82, S74–S75 (2007).
   Web of Science ®Google Scholar
• Bourhis J, Pignon J-P. Update of MACH-NC (meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemoradiotherapy. J. Clin. Oncol.22, 5505 (2007).
   Google Scholar
• Lefebvre JL. Laryngeal preservation in head and neck cancer: multidisciplinary approach. Lancet Oncol.7, 747–755 (2006).
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet355, 949–955 (2000).
   PubMed Web of Science ®Google Scholar
• Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative group. J. Natl Cancer Inst.88, 890–899 (1996).
   PubMed Web of Science ®Google Scholar
• Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl Cancer Inst.86, 265–272 (1994).
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357, 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med.357, 1695–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Laurie SA, Weinstein GS et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J. Clin. Oncol.24, 3693–3704 (2006).
   PubMed Web of Science ®Google Scholar
• Zbaren P, Weidner S, Thoeny HC. Laryngeal and hypopharyngeal carcinomas after (chemo)radiotherapy: a diagnostic dilemma. Curr. Opin. Otolaryngol. Head Neck Surg.16, 147–153 (2008).
   PubMed Web of Science ®Google Scholar
• Henk JM. Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin. Oncol. (R. Coll. Radiol.)9, 308–312 (1997).
   PubMedGoogle Scholar
• El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J. Clin. Oncol.14, 838–847 (1996).
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J. Clin. Oncol.25, 4096–4103 (2007).
   PubMed Web of Science ®Google Scholar
• Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int. J. Radiat. Oncol. Biol. Phys.47, 1–12 (2000).
   PubMed Web of Science ®Google Scholar
• Hey J, Setz J, Gerlach R et al. Effect of cisplatin on parotid gland function in concomitant radiochemotherapy. Int. J. Radiat. Oncol. Biol. Phys.75, 1475–1480 (2009).
   PubMedGoogle Scholar
• Budach V, Stuschke M, Budach W et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil–mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J. Clin. Oncol.23, 1125–1135 (2005).
   PubMed Web of Science ®Google Scholar
• Huguenin P, Beer KT, Allal A et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J. Clin. Oncol.22, 4665–4673 (2004).
   PubMed Web of Science ®Google Scholar
• Machtay M, Rosenthal DI, Hershock D et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II trial. J. Clin. Oncol.20, 3964–3971 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen NP, Sallah S, Karlsson U et al. Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues. Cancer94, 1131–1141 (2002).
   PubMed Web of Science ®Google Scholar
• Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.50, 1161–1171 (2001).
   PubMed Web of Science ®Google Scholar
• Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol.21, 320–326 (2003).
   PubMed Web of Science ®Google Scholar
• Hitchcock YJ, Tward JD, Szabo A et al. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int. J. Radiat. Oncol. Biol. Phys.73, 779–788 (2009).
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res.62, 7350–7356 (2002).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Harrington KJ, El-Hariry IA, Holford CS et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol.27, 1100–1107 (2009).
   PubMed Web of Science ®Google Scholar
• Rivera F, Garcia-Castano A, Vega N et al. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev. Anticancer Ther.9(10), 1421–1428 (2009).
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Allen AM, Posner MR et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann. Oncol.21(2), 342–347 (2009).
   PubMedGoogle Scholar
• Helleday T, Petermann E, Lundin C et al. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer8, 193–204 (2008).
   PubMed Web of Science ®Google Scholar